T/R potency <5% [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2022-09-09 12:48 (591 d 22:59 ago) – Posting: # 23282
Views: 2,406

Hi Achievwin!
Unlike Health Canada, there is no provision for potency correction in FDA.
So if the difference is more, there is higher probability to find difference in PK parameters for treatments, which ultimately affects BE outcome.
It's best to have less difference in Assay of Test and Reference for any BE study.
Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
22,990 posts in 4,826 threads, 1,664 registered users;
59 visitors (0 registered, 59 guests [including 3 identified bots]).
Forum time: 11:48 CEST (Europe/Vienna)

If you don’t like something change it;
if you can’t change it, change the way you think about it.    Mary Engelbreit

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5